Select Language
Free Registration
My Cart

NoV(GII.4)VP1

NoV(GII.4)VP1 Product List

  • Product Category

    Antibody (1)

  • Product Status

    Launched (1)

  • Species

    Mouse (1)

  • Tag

    - (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
NO1-MY2186
Mouse
HEK293
Monoclonal Anti-Human NoV(GII.4)VP1 Antibody, Mouse IgG1 (1C2) (MALS verified) Add to Cart
Total: 1
  • 1

NoV(GII.4)VP1 Background

Noroviruses are icosahedral viruses in the family Caliciviridae, with a single-stranded, positive-sense RNA genome. Noroviruses are genetically diverse and can infect a wide variety of hosts. Norovirus is a leading cause of acute gastroenteritis (AGE) globally. They are divided into 10 genogroups (GI to GX) based on VP1 amino acid sequence. Each genogroup is subdivided into genotypes based on capsid amino acid sequence, with 49 genotypes currently described. Noroviruses can also be classified based on their RdRp (“polymerase”) sequence, with at least 60 P-types currently circulating.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
EpacadostatINCB-024360; 71596A9R13 (UNII code); INCB-24360Phase 3 ClinicalIncyte CorpCarcinoma, Squamous Cell; Sarcoma; Peritoneal Neoplasms; Thymus Neoplasms; Colorectal Neoplasms; Leukemia, B-Cell; Lymphoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Urogenital Neoplasms; Glioma; Urethral Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Thymoma; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Transitional Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Abdominal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Neoplasms; Nasopharyngeal Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms
Details
PuliginuradYL-90148Phase 3 ClinicalYL-PharmaHyperuricemia; Gout
Details
LinrodostatONO-7701; BMS-986205Phase 3 ClinicalBristol-Myers Squibb CompanySolid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Glioblastoma; Skin Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Mouth Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Laryngeal Diseases
Details
IO-102IO-102Phase 2 ClinicalHerlev Hospital, Merck Sharp & Dohme Corp, Io Biotech ApsCarcinoma, Squamous Cell; Mouth Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma
Details
Indoximod1-MT; D-1MT; NLG-001; NLG-8189; NSC-721782Phase 2 ClinicalNewlink Genetics CoBrain Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Glioma; Diffuse Intrinsic Pontine Glioma; Gliosarcoma; Prostatic Neoplasms; Solid tumours; Breast Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Medulloblastoma; Ependymoma
Details
RiMO-301RiMO-301Phase 2 ClinicalThe University Of ChicagoHead and Neck Neoplasms; Neoplasms
Details
SHR-9146HTI-1090; SHR-9146Phase 1 ClinicalSolid tumours; Neoplasms
Details
KHK-2455KHK-2455Phase 1 ClinicalKyowa Hakko Kirin Co LtdSolid tumours; Carcinoma; Neoplasms; Carcinoma, Transitional Cell
Details
LPM-3480226LY-01013; LPM-3480226Phase 1 ClinicalLuye Pharma Group LtdSolid tumours
Details
DN-1406131DN-131; DN-1406131Phase 1 ClinicalJiangxi Qingfeng Pharmaceutical Industry Co Ltd, Shanghai De Novo Pharmatech Co LtdSolid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
NLG802NLG-802Phase 1 ClinicalLankenau Institute For Medical ResearchSolid tumours
Details
MK-7162MK-7162Phase 1 ClinicalMerck Sharp & Dohme CorpSolid tumours
Details
RiMO-401RiMO-401Phase 1 ClinicalCoordination Pharmaceuticals IncSolid tumours
Details
NavoximodNLG-919; RG-6078; GDC-0919Phase 1 ClinicalLankenau Institute For Medical Research, Lumos Pharma IncSolid tumours
Details
  • Product List
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland